AI assistant
Indaptus Therapeutics, Inc. — Director's Dealing 2021
Aug 2, 2021
35475_dirs_2021-08-02_a2c0a1f2-403c-469d-9fb8-d56419b451f1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Intec Parent Inc. (NTEC)
CIK: 0001857044
Period of Report: 2021-07-23
Reporting Person: Linscott Walt Addison (Chief Business Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $684.8 | 2027-10-23 | Common Stock (750) | Direct | |
| Stock Option (right to buy) | $684.8 | 2027-12-11 | Common Stock (1750) | Direct | |
| Stock Option (right to buy) | $610.4 | 2026-01-22 | Common Stock (1125) | Direct | |
| Stock Option (right to buy) | $72.0 | 2026-09-13 | Common Stock (2500) | Direct | |
| Stock Option (right to buy) | $34.3 | 2027-02-17 | Common Stock (1125) | Direct | |
| Stock Option (right to buy) | $25.72 | 2027-09-16 | Common Stock (1250) | Direct |
Footnotes
F1: The stock options are fully vested and are exercisable.
F2: The options vest over a period of three years from January 22, 2019, 33.3% on the first anniversary of such date and 8.33% every three months thereafter, ending January 22, 2022.
F3: The options vest over a period of three years from September 13, 2019, 33.3% on the first anniversary of such date and 8.33% every three months thereafter, ending September 13, 2022.
F4: The options vest over a period of three years from February 17, 2020, 33.3% on the first anniversary of such date and 8.33% every three months thereafter, ending February 17, 2023.
F5: The options vest and become exercisable in full on December 31, 2021.